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Background: [18F]ﬂuorodeoxyglucose-positron emission tomography (PET) is emerging as a strong diagnostic and
prognostic tool in follicular lymphoma (FL) patients.
Patients and methods: In a subset analysis of the FOLL05 trial (NCT00774826), we investigated the prognostic role of
post-induction PET (PI-PET) scan. Patients were eligible to this study if they had a PI-PET scan carried out within 3
months from the end of induction immunochemotherapy. Progression-free survival (PFS) was the primary study end
point.
Results: A total of 202 patients were eligible and analysed for this study. The median age was 55 years (range 33–75).
Overall, PI-PET was deﬁned as positive in 49 (24%) patients. Conventional response assessment with CT scan was sub-
stantially modiﬁed by PET: 15% (22/145) of patients considered as having a complete response (CR) after CT were con-
sidered as having partial response (PR) after PI-PET and 53% (30/57) patients considered as having a PR after CT were
considered as a CR after PI-PET. With a median follow-up of 34 months, the 3-year PFS was 66% and 35%, respectively,
for patients with negative and positive PI-PET (P < 0.001). At multivariate analysis, PI-PET (hazard ratio 2.57, 95% conﬁ-
dence interval 1.52–4.34, P < 0.001) was independent of conventional response, FLIPI and treatment arm. Also, the
prognostic role of PI-PET was maintained within each FLIPI risk group.
Conclusions: In FL patients, PI-PET substantially modiﬁes response assessment and is strongly predictive for the risk of
progression. PET should be considered in further updates of response criteria.
Key words: FDG-PET, follicular lymphoma, prognosis
introduction
Follicular lymphoma (FL) is the most common indolent B-cell
lymphoma and accounts for 10%–20% of all lymphomas in
western countries [1]. The availability of rituximab has
substantially changed FL therapeutic approaches. Several trials
have clearly demonstrated that the addition of rituximab to
chemotherapy can prolong survival when compared with
chemotherapy alone [2–5]. Also, the beneﬁt of maintenance
therapy has been recently suggested [6].
Although the outcome of patients with FL has clearly
improved, heterogeneity in patients’ outcome still remains.
Currently, FLIPI and FLIPI2 are the most widely used prognos-
tic systems [7, 8]. In addition, several biological factors as, for
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example, highly sensitive polymerase chain reaction-based ana-
lysis, have been suggested as relevant prognostic factors [9]. So
far, however, none of the current available prognostic factors
has been used to guide clinical decisions in FL.
[18F]ﬂuorodeoxyglucose-positron emission tomography
(FDG-PET) has recently emerged as a powerful functional
imaging tool in staging and response assessment in Hodgkin’s
lymphoma and diffuse large B-cell lymphoma [10, 11].
Although FL is considered as an FDG avid disease, the literature
concerning the role of PET in FL was scarce for many years and
this tool was not recommended as a routine procedure [11].
Recently, FDG-PET was shown to add details in the staging [12]
and to be an independent prognostic factor for lymphoma pro-
gression and survival when used at the end of induction immu-
nochemotherapy (ICT) in patients with FL [13, 14].
In 2005, the Fondazione Italiana Linfomi (FIL) started the
prospective randomized phase III trial named FOLL05 that
compared R-CVP, R-CHOP and R-FM for patients with newly
diagnosed stage II/IV FL [15]. Although PET was not included
among diagnostic and response assessment procedures, several
patients underwent PET scan after initial ICT. Therefore, we
retrospectively investigated the prognostic role of PET scan
carried out after initial ICT in patients with advanced stage,
active FL.
patients andmethods
inclusion and exclusion criteria
The present study was designed as a subset analysis of FL patients enrolled
in the phase III trial FOLL05 (NCT00774826), in which patients were rando-
mized to receive R-CVP, R-CHOP or R-FM (rituximab, ﬂudarabine and
mitoxantrone) [15]. The FOLL05 study was conducted among 60 institu-
tions in Italy and accrual completed on September 2010 with the enrolment
of 534 patients. According to the FOLL05 trial, no maintenance therapy
with rituximab or any other agent was allowed. This study was submitted
and approved by ethic committee and patients were required to sign for
informed consent.
In order to be considered for this current study, patients were required to
be fully eligible and randomized in the FOLL05 trial, that is to be between 18
and 75 years, have Ann Arbor stage II to IV, previously untreated and have
active disease deﬁned according to published criteria [15]. For the purposes
of this study, patients should have available data on post-induction PET (PI-
PET). PET scanning was not included among FOLL05 study procedures but
was allowed if the facility was available at the participating institution. None
of the FOLL05 results was based on PET results. To be included in the
present study, PI-PET had to be carried out from 10 days to 3 months after
the last cycle of induction treatment.
All data on baseline features, treatment details, response and follow-up
were retrieved from the original FOLL05 data set.
PET results
For the purpose of this study, data were obtained on all PET scans carried
out before (baseline PET: B-PET), and at the end of induction ICT (PI-
PET). All local PET reports were centralized at the FIL datacentre; a positive
or negative PI-PET was deﬁned by the local investigators interpretation of
the nuclear physician’s scan report that was based on a visual qualitative as-
sessment; no data were available on functional ﬁndings [10]. All the centres
were included in FIL network of nuclear medicine that adhere to stringent
quality criteria and undergo periodic quality assessment. A positive or
negative PET scan was deﬁned on the original report and reviewed by SL,
AV and QM blinded of patient outcome and discussed with the nuclear
physician in uncertain cases. We considered as positive all lesions that were
described in the local report. Cases not clearly positive or negative were
deﬁned as inconclusive and excluded from subsequent analyses. All PET
scans were PET/CT.
end point deﬁnition
The primary end point was progression-free survival (PFS), which was calcu-
lated as the time from the date of ﬁrst treatment until the date of lymphoma
progression, relapse, death from any cause and last follow-up visit.
Secondary end points included response rates, disease-free survival (DFS)
and overall survival (OS). Response was deﬁned according to 1999 inter-
national criteria and based on the use of CT scan only [16]. DFS was calcu-
lated for those achieving complete (CR) or partial remission (PR) according
to conventional assessment and was deﬁned as time from the date of remis-
sion until relapse, death or last contact. OS was calculated for all patients as
time from the date of diagnosis until death, or last follow-up visit.
statistical analysis
Standard descriptive analyses were carried out. For a crude association ana-
lysis, categorical data were analysed using the χ2 or Fisher’s exact test (two-
sided). Cohen’s κ-statistic was used to verify agreement between PET and
CT results. The level of agreement was deﬁned by Koch Landis scale.
Survival curves were estimated using the Kaplan–Meier method and com-
pared using the log-rank test. Univariate and multivariate Cox regression
analyses were conducted to verify the prognostic role of PI-PET regarding
PFS and DFS, adjusted for relevant prognostic clinical variables and treat-
ment arm. OS was only analysed with univariate analysis due to the low
number of events. Two-tailed P-values of <0.05 were considered statistically
signiﬁcant. Statistical analysis was carried out with SPSS software (version
18.0, Chicago, IL).
results
Two hundred and forty-four out of 534 patients enrolled in the
FOLL05 trial had a PI-PET carried out and were initially iden-
tiﬁed for this study. Among them, 10 patients were subsequently
excluded because they were considered ineligible for the
FOLL05 study, and 4 patients, because PET was carried out after
clinical progression. From the remaining 230 patients, 21
patients were excluded because PI-PET was carried out outside
the admitted time range of the study and additional 7 patients
were excluded because of inconclusive results for PI-PET. A
total of 155 patients also had an available B-PET. Outcome ana-
lysis was carried out on all 202 cases, regardless if they had
undergone a baseline PET or not, because of the high sensitivity
of PET scans at diagnosis and similarly to what was done in a
similar study [13].
Baseline patients’ characteristics are shown in Table 1. The
median age was 56 years (range 33–75). After a median follow-
up of 34 months (range 7–66), the 3-year PFS, DFS and OS for
the study population was 60% [95% conﬁdence interval (CI)
51%–67%], 53% (95% CI 43%–62%) and 99% (95% CI 94%–
100%), respectively. Clinical characteristics of the study popula-
tion did not differ from that of the FOLL05 study. Also, no dif-
ference was found in response rates assessed by CT scan-only
for patients in this study compared with patients enrolled in the
FOLL05 (CR rate, 72% versus 69%, P = 0.62) and no difference
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was found in PFS (58% versus 61%, P = 0.61) between the two
groups, indicating no response-selection bias.
conventional and PET-based response assessment
According to conventional response criteria (CT only), 145
patients achieved CR (72%) and 48 (24%) patients achieved PR,
with an overall response rate of 96%; 9 (4%) patients had stable
disease/progressive disease. Forty-seven (23%) patients among
those who achieved a CR were classiﬁed as CRu.
PI-PET was carried out at a median of 36 days (range 10–92)
after the last dose of ICT. Overall, PI-PET was deﬁned as nega-
tive in 153 (76%), and positive in 49 (24%) patients. PI-PET
positivity was referred to lymph node or nodal areas in 40 (82%)
cases; in 14 cases, PI-PET positivity was described at extranodal
sites and was the only residual site in 9 cases: among these cases,
bone was the most frequent site (4 cases). Comparison of base-
line characteristics, treatment and response assessment accord-
ing to PI-PET is shown in Table 1. No difference regarding
baseline and prognostic characteristics was found between posi-
tive and negative PI-PET patients, except for an increased pro-
portion of patients with hemoglobin level <12 g/dl and of
female patients in the group of positive PI-PET. Agreement rate
between PET and CT was 74% with κ-value of 0.336 (fair agree-
ment). Using PI-PET, 30 out of the 57 patients not classiﬁed as
CR according to CT were converted into CR (53%) and 22 out
of the 145 classiﬁed as CR, were reclassiﬁed into PR (15%). The
frequency of positive PI-PET increased from the categories of
poorer responses to those of better responses (Table 2). Among
CRu patients, 19% (9/47) were PI-PET positive. No difference in
terms of PI-PET results was found between CR and CRu cases
(P = 0.45).
analysis of survival
PFS and DFS. Patients who presented a negative PI-PET had a
signiﬁcantly superior PFS (3-year: 66%; 95% CI 57%–74%) than
those who presented a positive PI-PET [35%; 95% CI 18%–52%;
hazard ratio (HR) 2.59, 95% CI 1.59–4.24] (P < 0.001). The
median PFS was 29 months for patients with a positive PI-PET
and not attained for negative PI-PET, respectively (Figure 1).
Also, patients who showed a negative PI-PET had a signiﬁcantly
superior 3-year DFS of 57% (95% CI 46%–67%) compared with
36% (95CI 19%–54%) of those who presented a positive PI-PET
(HR 2.26: 95% CI 1.34–3.80) (P = 0.002). The median DFS was
45 and 24 months between patients with a negative and positive
PI-PET, respectively. By using the conventional response
criteria (CT only), patients achieving CR had a better 3-year
PFS when compared with those achieving less than CR (3-year
PFS: 63%, 95% CI 53%–72% versus 51%, 95% CI 35%–64%;
Table 2. Results of post-induction positron emission tomography
by CT response in 202 patients with evaluable post-induction
positron emission tomography (PI-PET)
CR, n = 145
(%)
PR, n = 48
(%)
SD/PD, n = 9
(%)
PI-PET negative 123 (85) 27 (56) 3 (33)
PI-PET positive 22 (15) 21 (44) 6 (67)
Pearson’s χ2 test = P < 0.001; test for trend Cochran–Armitage
P < 0.001.
CR, complete remission; PR, partial remission; SD, stable disease;
PD, progressive disease; PI-PET: post-induction PET.
Table 1. Baseline characteristics, treatment and response assessment of all patients and according to post-induction positron emission tomography
results (PI-PET)
All patients, n = 202 (%) PI-PET negative, n = 153 (76%) PI-PET positive, n = 49 (24%) P-value
Age >60 65 (32) 46 (30) 19 (39) 0.29
Male sex 96 (48) 79 (52) 17 (35) 0.05
Ann Arbor stage III–IV 186 (92) 142 (93) 44 (90) 0.54
Hemoglobin <12g/dl 31 (15) 18 (12) 13 (26) 0.02
ECOG PS ≥ 2 9 (5) 7 (5) 2 (4) 1.0
Bulky disease (>6 cm) 64 (32) 45 (29) 19 (39) 0.22
BM involvement 102 (51) 75 (49) 27 (55) 0.51
Increased B2-microglobulin 85 (42) 63 (41) 22 (45) 0.74
Increased LDH 42 (21) 28 (18) 14 (29) 0.29
FLIPI 3–5 71 (35) 51 (33) 20 (41) 0.39
First treatment
R-CVP 66 (33) 51 (33) 15 (31) 0.78
R-CHOP 62 (30) 48 (32) 14 (29)
R-FM 74 (37) 54 (35) 20 (40)
PS, performance status; BM: bone marrow; FLIPI, follicular lymphoma international prognostic index; LDH, lactic dehydrogenase; R-CVP, rituximab,
cyclophosphamide, vincristine and prednisone; R-CHOP, rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone; R-FM, rituximab,
ﬂudarabine and mitoxantrone.
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P = 0.049), respectively. Comparing PI-PET and CT response,
the prognostic role of PI-PET was more relevant for patients
classiﬁed as PR, while no differences were observed comparing
patients in CR versus CRu (data not shown). Multivariate Cox
regression analyses for PFS and DFS were carried out in order to
verify the prognostic role of PI-PET adjusted by relevant
prognostic factors and treatment arm. In the ﬁnal multivariate
Cox regression analysis, PI-PET was an independent prognostic
factor for PFS and DFS, along with FLIPI and conventional
response and type of ICT (Table 3).
Finally, combining the information of FLIPI and PI-PET, the
information of PI-PET allowed the identiﬁcation of different
risk groups within each FLIPI risk group (supplementary
Figure S1, available at Annals of Oncology online).
overall survival
At the time of the analysis, six patients died: three in the nega-
tive post-induction PET group and three in the positive post-
induction PET group. The causes of death were disease progres-
sion in four patients and secondary neoplasia in two. The 3-year
OS for all the 202 patients was 99% (95% CI 94%–100%).
discussion
The present study shows that PI-PET can inﬂuence response as-
sessment and represents a robust and independent prognostic
factor in predicting PFS and DFS in patients with FL treated
with ICT. Overall, for the 76% of patients who had a negative
PI-PET, a 3-year PFS of 66% was foreseen, unlike the unsatisfac-
tory 35% 3-year PFS observed for the remaining 24% of patients
with a positive PI-PET. Noteworthy, the predictive power of PI-
PET was not inﬂuenced by other well-known relevant clinical
prognostic factors, including type of ICT, conventional response
and FLIPI. Finally, PI-PET was prognostic, even within each
FLIPI risk group (scores 0–2 versus 3–5).
Although FL has been always described as an FDG-avid
disease [17], the prognostic role of PET in FL has only recently
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Figure 1. Progression-free survival in 202 patients with follicular lymphoma according to post-induction positron emission tomography.
Table 3. Multivariate Cox analysis for progression-free survival (PFS) and disease-free survival (DFS) in patients evaluated by PI-PET
PFS (n = 202) DFS (n = 193)
HR 95% CI P-value HR 95% CI P-value
PI-PET + 2.57 1.52–4.34 <0.001 2.23 1.28–3.92 0.005
FLIPI 3–5 1.80 1.13–2.89 0.014 2.07 1.27–3.37 0.003
Response <CR (CT only) 1.17 0.70–1.95 0.549 1.18 0.67–2.06 0.565
R-CVPa 1.84 1.15–2.95 0.011 2.08 1.27–3.39 0.003
HR, hazard ratio; CI, conﬁdence interval; PI-PET, post-induction PET ; FLIPI, follicular lymphoma prognostic index; CR, complete remission; CT,
computed tomography; R-CVP, rituximab, cyclophosphamide, vincristine and prednisone; R-CHOP, rituximab, cyclophosphamide, doxorubicine,
vincristine and prednisone; R-FM, rituximab, ﬂudarabine and mitoxantrone.
aR-CVP versus (R-CHOP and R-FM).
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been analysed. In one large retrospective study carried out on
122 patients from the PRIMA trial, Trotman et al. [13] showed
that, at a median follow-up of 42 months, the 26% of patients
with a positive PET after induction ICT had a signiﬁcantly infer-
ior PFS of 32.9% compared with the 70.7% in those remaining
PET negative. More recently, a prospective study on 121 patients
conducted by the Lysa group with the speciﬁc aim of investigat-
ing the role of PET in response assessment after R-CHOP
showed that 2-year PFS was 61% in positive PET (24% of cases)
and 87% for those with negative PET [14].
The present study is the largest one investigating the role of
PET in response assessment after induction ICT in patients with
FL. Similar to Trotman’s study, we conducted a retrospective
subset analysis of a randomized trial, treatment was not homo-
genous, and PET assessment was based on local interpretation.
Unlike the Trotman study, in our series, none of the patients
was treated with maintenance rituximab, which was not allowed
in the original FOLL05 design. Among the three studies, the
Lysa group study was the only prospective one. It included cen-
tralization of PET scans for review and the results were reported
using the Deauville ﬁve-point scale. As with our study, patients
did not receive maintenance after ICT. Notwithstanding the
methodological differences, the results of the three studies are
absolutely superimposable. The rate of PET positivity was very
similar, being 24%, 26% and 24% in our study, the Trotman’s
and Lysa experience, respectively. Likewise, the magnitude of
the increased risk of progression determined by post-induction
result was very similar as well as the observed PFS. Finally, the
prognostic role of PET was independent of relevant known
prognostic factors, including FLIPI, in all three studies. In add-
ition, OS was also investigated as a secondary end point and PI-
PET conﬁrmed to be predictive in the Trotman and Lysa trials.
In our analysis, we were not able to analyse OS as an end point
due to the low number of events [13, 14].
Similar to other lymphoma subtypes, a relevant question is
how PET response assessment should be evaluated in patients
with FL. Looking at the results of the three largest studies, it
does not seem that the methodology used to deﬁne response
really matters when identifying patients with different progno-
sis. However, in order to provide comparable results, method-
ology must be standardized and reproducible. As clearly shown
in the Lysa study, the Deauville score with a cut-off at 4 seems to
provide excellent results, both in terms of reproducibility and
accuracy [14].
Our results conﬁrm that the incorporation of PI-PET in re-
sponse assessment [11] is suitable and should be considered in
further updates of response criteria. However, with available
data on the use of PI-PET for response assessment, some rele-
vant questions should be answered. First, most of available data
on the prognostic role of PI-PET come from patients treated
with R-CHOP or R-CVP who are not treated with maintenance
therapy; PI-PET results should then be carefully applied to
chemotherapy regimens different from R-CHOP or R-CVP, in-
cluding R-bendamustine, and, most important, other novel
promising treatment modalities (R-lenalidomide, or drugs tar-
geting the B-cell-receptor pathway). Regarding maintenance,
available data do not allow to deﬁne if the prolonged use of
rituximab has an impact on outcome if they achieve a negative
PI-PET. Looking at the poor PFS of patients with positive
PI-PET, however, it seems reasonable to consider these patients
as affected by high-risk FL and deﬁne appropriate clinical trials
to investigate the role of more aggressive approaches than
simple rituximab maintenance therapy, considering the use of
radioimmunotherapy, or the anticipation of salvage convention-
al therapies or of investigational new drugs. Finally, in FL, FDG-
PET results should also be compared and integrated with results
from molecular assessment of minimal residual disease that has
been shown to be prognostic in several studies [9]. So far, no
data are available comparing PET and MRD analysis in the
same patients, and such studies are strongly warranted.
In conclusion, based on the results of our study, we
conﬁrmed that PI-PET improves response assessment in
patients with FL treated with conventional immunochemother-
apy and strongly support its inclusion in response criteria for FL
similarly to Hodgkin lymphoma and DLBCL. Based on the
prognostic role of PET response, future studies should be
designed to assess if with a PET-driven approach, it will be pos-
sible to further improve patients’ outcome, aiming in particular
at improving the high risk of progression observed for PET-
positive patients.
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Preference for involvement in treatment decisions and
request for prognostic information in newly diagnosed
patients with higher-risk myelodysplastic syndromes†
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Background: The main objective of this study was to assess preferences for involvement in treatment decisions and
requests for prognostic information in newly diagnosed higher-risk myelodysplastic syndrome (MDS) patients.
Patient and methods: This was a prospective cohort observational study that consecutively enrolled MDS patients
with an international prognostic scoring system (IPSS) risk category of intermediate-2 or high risk (summarized as ‘higher
risk’). The control preference scale was used to assess patient preferences for involvement in treatment decisions, and
whether a request by patients for prognostic information during consultation was made, was also recorded. All of the
patients were surveyed at the time of diagnosis before receiving treatment. Univariate and multivariate analyses were
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